



**Dr. med. Urs Hess**

### **Kontakt**

Dr. med. Urs Hess  
Rorschacherstr. 95  
9007 St. Gallen  
Switzerland

T +41 71 494 10 71  
urs.hess@kssg.ch

### **Bereiche**

Medizinische Onkologie und Hämatologie

### **Position**

Leitender Arzt, Stv. Chefarzt

### **Forschungsgebiet**

Hämatologische Neoplasien

### **Mitgliedschaften**

American Society of Hematology  
European Blood and Marrow Transplantation Group  
Swisstransplant (Stiftungsrat)  
Schweizerische Gesellschaft für Hämatologie  
Schweizerische Gesellschaft für Medizinische Onkologie  
FMH

## Publikationen (26)

Ossenkoppele G, Pabst T, Oosterveld M, Obbergh F, Nijziel M, Moors I, Kooy M, Maertens J, Loosdrecht A, Legdeur M, Poel M, Sinnige H, Spertini O, Norden Y, Stussi G, Westerweel P, Weerd O, Vellenga E, Vekemans M, Velden W, Tick L, Terpstra W, Lammeren-Venema D, Kuball J, Deeren D, Chalandon Y, Brouwer R, Breems D, Borne P, Biemond B, Bargetzi M, Manz M, Löwenberg B, Efthymiou A, Gjertsen B, Graux C, Klift M, Klein S, Jongen-Lavrencic M, Jie A, Jaspers A, Hoogendoorn M, Hess U, Heim D, Gregor M, Janssen J. Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. *Cancers (Basel)* 2021; 13

Benz R, O'Meara Stern A, Cantoni N, Bargetzi M, Bianchi-Papina E, Rossi D, Passweg J, Lohri A, Berardi S, Feller A, Rauch D, Blum S, Mey U, Arn K, Andres M, Pabst T, Baumann M, Novak U, Hitz F, Hess U, Zenhausern R, Chalandon Y, Stussi G. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. *Blood Adv* 2020; 4:3699-3707.

Passweg J, Masouridi-Levrat S, Müller A, Nair G, Pabst T, Renner C, Schmidt A, Stussi G, Nicoloso de Faveri G, Schanz U, Leibundgut K, Hess U, Heim D, Baldomero H, Ansari M, Baerlocher G, Bargetzi M, Chalandon Y, Duchosal M, Gerull S, Güngör T, Halter J, For The Swiss Blood Stem Cell Transplantation Group Sbst. Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016. *Swiss Med Wkly* 2018; 148:w14589.

Schnegg-Kaufmann A, Bonadies N, Arndt V, Stussi G, Passweg J, Chalandon Y, Spertini O, Hess U, Bargetzi M, Efthymiou A, Gregor M, Manz M, Rovó A, Baldomero H, Feller A, NICER Working Group. Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013. *Cancer Epidemiol* 2017; 52:55-62.

Meissner J, Montoto S, Samaras P, Robinson S, Pioltelli P, Pabst T, Mohty M, Ludwig H, Hess U, Finke J, Delage J, Cornelissen J, Abecasis M, Laboure G, Kanfer E, Boumendil A, Dietrich S, Finel H, Dreger P. Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience. *Bone Marrow Transplant* 2016; 52:650-652.

Gössi F, Schardt J, Bargetzi M, Berthold D, Hess U, Stenner F, Mischo A, Panagiotis S, Zweifel M, Spahn M, Pabst T. Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse. *Bone Marrow Transplant* 2016; 52:334-336.

Baumgartner A, Mueller B, Stanga Z, Hess U, Duchosal M, Pabst T, Wannesson L, Limonta A, Pichard C, Chalandon Y, Samaras P, Schanz U, Passweg J, Medinger M, Zueger N, Bargetzi A, Bargetzi M, Schuetz P. Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison. *Nutrition* 2016; 35:43-50.

Maury S, Braun T, Marolleau J, Cahn J, Chalandon Y, Lhéritier V, Beldjord K, Béné M, Ifrah N, Dombret H, Pignon J, Vey N, Hess U, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. *N Engl J Med* 2016; 375:1044-53.

Samaras P, Zander T, Taverna C, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Hess U, Heim D, Duchosal M, Betticher D, Bargetzi M, Renner C. Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. *Swiss Med Wkly* 2015; 145:w14100.

Terwijn M, Graux C, Bargetzi M, Legdeur M, Kuball J, de Weerd O, Chalandon Y, Hess U, Verdonck L, Gratama J, Oussoren Y, Scholten W, Slomp J, Snel A, Vekemans M, Löwenberg B, Ossenkoppele G, Wijermans P, van Gelder M, van Putten W, Kelder A, van der Velden V, Brooimans R, Pabst T, Maertens J, Boeckx N, de Greef G, Valk P, Preijers F, Huijgens P, Dräger A, Schanz U, Jongen-Lavrecic M, Biemond B, Passweg J, Schuurhuis G. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. *J Clin Oncol* 2013; 31:3889-97.

Passweg J, Schanz U, Stussi G, Stern M, Renner C, Pabst T, Ozsahin H, de Faveri G, Leibundgut K, Hess U, Güngör T, Gratwohl A, Duchosal M, Chalandon Y, Bucher C, Bargetzi M, Baldomero H, SBST (Swiss Blood Stem Cell Transplantation Group). Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries. *Swiss Med Wkly* 2013; 143:w13757.

Hess U. Leukämie muss kein Todesurteil mehr sein. *Schweizer Zeitschrift für Onkologie* 2013; 2/2013

Gallerani E, D'Incalci M, Sala F, Cereda R, Marsoni S, de Braud F, Driessen C, Böhm S, Martinelli G, Delmonte A, Hess U, Noberasco C, Marangon E, Brunelli D, Zucchetti M, Sessa C. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. *Eur J Cancer* 2012; 49:290-6.

Wannesson L, Samaras P, Renner C, Pabst T, Lerch E, Hess U, Heim D, Cerutti A, Cairoli A, Bargetzi M, Zucca E. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). *Leuk Lymphoma* 2012; 54:36-40.

Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof D, Heizmann M, Stahel R, Stupp R, Okkinga E, Bassi S, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. *J Clin Oncol* 2010; 28:4480-4.

Ludwig H, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Hess U, Harousseau J, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Zweegman S. Current multiple myeloma treatment strategies with novel agents: a European perspective. *Oncologist* 2010; 15:6-25.

Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof H, Heizmann M, Stahel R, Stupp R, Okkinga E, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98. *J Clin Oncol* 2010; 28:4480-4484.

Zenhausern R, Rufener B, Bargetzi M, Leoncini L, Hess U, Meyer-Monard S, Heim D, Solenthaler M, Schmitz S, Tobler A. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). *Leukemia & lymphoma* 2009;1-11.

Hess U. Grosse Behandlungsfortschritte beim Myelom - Trend zeigt Richtung risikoadaptierte Therapie. *Onkologie* 2009; 2:22-25.

Hess U. Viel Bewegung in der Therapie der Myelodysplastischen Syndrome. *Leading Opinions Hämatologie / Onkologie* 2009; 1:52-55.

Zenhäusern R, Tobler A, Leoncini L, Kovacovic T, Bargetzi M, Hess U, Gratwohl A, Meyer-Monard S, Solenthaler M, Rufibach K, von Rohr A, Swiss Group for Clinical Cancer Research (SAKK). Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32/95. *Leukemia & lymphoma* 2009; 50:133-6.

Laurencet F, Zulian G, Plancherel C, Luthi J, Fey M, Cerny T, Hess U, Rufener B, Ballabeni P, Swiss Group for Clinical Research (SAKK). The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas. *Acta haematologica* 2007; 117:40-7.

Hess U. [The plasma cell myeloma--molecular pathogenesis and target therapies]. *Ther Umsch* 2006; 63:233-6.

Beyer V, van Melle G, Schmidt P, Schanz U, Laurencet F, Chapuis B, Hess U, Hitz F, Gregor M, Pugin P, Tobler A, Solenthaler M, Bougeon-Mamin S, Cabrol C, Parlier V, Mühlematter D, Jotterand M. Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published cases. *Cancer genetics and cytogenetics* 2005; 160:97-119.

Lugli A, Tichelli A, Von Juergenson S, Mach-Pascual S, Borisch B, Tinguely M, Hawle H, Korte W, Hess U, Passweg J, Gratwohl A, Cogliatti S, Ebnoether M, Dirnhofer S. Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia. *Hum Pathol* 2005; 36:91-100.

Ghielmini M, Vorobiof D, Bargetzi M, Lohri A, Helg C, Kovacsovics T, Stupp R, Zucca E, Hess U, Peccatori F, Martinelli G, Betticher D, Fey M, Waltzer U, Hummerjohann J, Pichert G, Cogliatti S, Schmitz S, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. *Blood* 2004; 103:4416-23.

## Projekte (11)

**Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase I/II trial**

*Klinische Forschung - 09.09.2015 - 31.03.2021*

*Automatisch geschlossen*

**HOVON 103 / SAKK 30/10 protocol Tosedostat**

*Klinische Forschung - 19.03.2015 - 19.03.2015*

*Automatisch geschlossen*

**A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of mediastinal radio-therapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)**

*Klinische Forschung - 02.10.2013 - 02.10.2017*

*Automatisch geschlossen*

**Master Protokoll: A Program of randomized phase II multicenter studies to assess the tolerability and efficacy of the addition of new drugs to standard induction chemotherapy in AML and RAEB  $\geq$  66 years and cery poor risk AML  $\geq$  years**

*Klinische Forschung - 09.02.2012 - 09.02.2016*

*Automatisch geschlossen*

**Therapieoptimierungsstudie in der Primärtherapie des frühen Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET**

*Klinische Forschung - 06.01.2011 - 31.12.2014*

*Automatisch geschlossen*

**Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) RAEB with IPSS (grösser gleich 1.5) A multicenter phase III trial**

*Klinische Forschung - 22.10.2010 - 31.12.2013*

*Automatisch geschlossen*

**Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukaemia**

*Klinische Forschung - 31.05.2010 - 31.01.2015*

*Automatisch geschlossen*

**Therapieoptimierungsstudie in der Primärtherapie des fortgeschrittenen Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET**

*Klinische Forschung - 05.10.2009 - 01.12.2012*

*Automatisch geschlossen*

**5-Azacytidine to treat acute myeloid leukemia in elderly or frail patients not suitable for intensive chemotherapy. A multicenter phase II trial**

*Klinische Forschung - 07.04.2009 - 30.04.2012*

*Automatisch geschlossen*

**Protocole multicentrique de traitement**

*Klinische Forschung - 01.11.2007 - 01.11.2015*

*Automatisch geschlossen*

**Randomisierter kontrollierter Vergleich von Imatinib vs. Imatinib und Interferon-Alpha vs. Imatinib 800 mg**

*Klinische Forschung - 27.09.2004 - 27.09.2010*

*Automatisch geschlossen*